1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Anemia - Pipeline Review, H2 2013

Anemia - Pipeline Review, H2 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 329 pages

Anemia - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Anemia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anemia. Anemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Anemia.
- A review of the Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Anemia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Anemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Anemia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Anemia - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Anemia Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Anemia 13
Anemia Therapeutics under Development by Companies 15
Anemia Therapeutics under Investigation by Universities/Institutes 22
Late Stage Products 24
Comparative Analysis 24
Mid Clinical Stage Products 25
Comparative Analysis 25
Early Clinical Stage Products 26
Comparative Analysis 26
Discovery and Pre-Clinical Stage Products 27
Comparative Analysis 27
Anemia Therapeutics - Products under Development by Companies 28
Anemia Therapeutics - Products under Investigation by Universities/Institutes 35
Companies Involved in Anemia Therapeutics Development 36
Johnson and Johnson 36
Hospira, Inc. 37
Medgenics Inc. 38
AMAG Pharmaceuticals, Inc. 39
Medinox, Inc. 40
Amgen Inc. 41
Eli Lilly and Company 42
GlaxoSmithKline plc 43
Sangart, Inc. 44
Rockwell Medical Technologies, Inc. 45
Daiichi Sankyo Company, Ltd 46
Lentigen Corporation 47
Sangamo BioSciences, Inc. 48
Gamida Cell Ltd. 49
FibroGen, Inc. 50
Reliance Life Sciences Pvt. Ltd. 51
Novartis AG 52
Astellas Pharma Inc. 53
Chong Kun Dang Pharmaceutical 54
Dong-A Pharmaceutical Co., Ltd. 55
Japan Tobacco Inc. 56
Sandoz GmbH 57
ViroPharma Incorporated 58
Zydus Cadila Healthcare Limited 59
Bayer AG 60
Zosano Pharma, Inc. 61
3SBio Inc. 62
Evotec Aktiengesellschaft 63
Ligand Pharmaceuticals Incorporated 64
PROLOR Biotech, Inc. 65
ReGenX Biosciences, LLC 66
Accentia Biopharmaceuticals, Inc. 67
ADVENTRX Pharmaceuticals 68
Alexion Pharmaceuticals, Inc. 69
Alnylam Pharmaceuticals, Inc 70
Zenotech Laboratories Limited 71
ProMetic Life Sciences Inc. 72
Lipoxen PLC 73
Boryung Pharmaceutical Co., Ltd. 74
Green Cross Corporation 75
Hanall Pharmaceutical Co., Ltd. 76
JCR Pharmaceuticals Co., Ltd. 77
CCM Duopharma Biotech Bhd. 78
Pluristem Therapeutics Inc. 79
Uni-Bio Science Group Ltd. 80
Panacea Biotec Limited 81
Affymax, Inc. 82
Panion and Bf Biotech Inc. 83
Myungmoon pharmaceutical Co.,Ltd. 84
Cellerant Therapeutics, Inc. 85
Advinus Therapeutics Pvt. Ltd. 86
Asterion Ltd 87
CIMAB S.A. 88
Prolong Pharmaceuticals 89
Acceleron Pharma, Inc. 90
SynZyme Technologies, LLC 91
Pieris AG 92
Xenon Pharmaceuticals Inc. 93
ERYtech Pharma 94
Archemix Corp. 95
HemaQuest Pharmaceuticals, Inc. 96
Akebia Therapeutics, Inc. 97
GENETIX Pharmaceuticals, Inc. 98
NOXXON Pharma AG 99
Morphogenesis, Inc. 100
NKT Therapeutics, Inc. 101
Bolder Biotechnology, Inc. 102
Palkion, Inc. 103
Acetylon Pharmaceuticals, Inc. 104
Emmaus Medical, Inc. 105
Avesthagen Limited 106
PharmaEssentia Corporation 107
Vifor Pharma Ltd. 108
AesRx, LLC. 109
Errant Gene Therapeutics, LLC 110
NAL Pharmaceuticals Ltd. 111
Anemia - Therapeutics Assessment 112
Assessment by Monotherapy Products 112
Assessment by Combination Products 113
Drug Profiles 114
darbepoetin alfa - Drug Profile 114
darbepoetin alfa - Drug Profile 116
darbepoetin alfa - Drug Profile 118
FG-2216 - Drug Profile 120
FG-2216 - Drug Profile 122
FG-4592 - Drug Profile 124
FG-4592 - Drug Profile 126
peginesatide - Drug Profile 128
PBF-1681 - Drug Profile 131
sotatercept - Drug Profile 134
GSK-1278863 - Drug Profile 136
panobinostat - Drug Profile 138
PRS-080 - Drug Profile 143
NuPIAO - Drug Profile 145
eculizumab - Drug Profile 146
eltrombopag olamine - Drug Profile 148
EPO Receptor Agonist - Drug Profile 151
recombinant human erythropoietin - Drug Profile 152
Pegylated Erythropoietin - Drug Profile 154
ACE-536 - Drug Profile 155
PBI-1402 - Drug Profile 156
erythropoietin biosimilar - Drug Profile 157
XEN-701 - Drug Profile 158
epoetin alfa - Drug Profile 159
HIF Stablilizer - Drug Profile 161
NOX-H94 - Drug Profile 162
SCPF - Drug Profile 164
ferumoxytol - Drug Profile 165
AKB-6548 - Drug Profile 167
CNTO-530 - Drug Profile 168
ErepoXen - Drug Profile 169
ErepoXen - Drug Profile 171
erythropoietin biosimilar - Drug Profile 173
ferric pyrophosphate - Drug Profile 174
ferric pyrophosphate - Drug Profile 176
BR-05001 - Drug Profile 178
Enhoxy - Drug Profile 179
Trichostatin A - Drug Profile 180
MX-1520 - Drug Profile 181
Sickle Cell Disease Program - Drug Profile 182
prasugrel hydrochloride - Drug Profile 183
Erythropoietin - Drug Profile 185
regadenoson - Drug Profile 186
HQK-1001 - Drug Profile 187
darbepoetin alfa biosimilar - Drug Profile 189
Drug For Anemia - Drug Profile 190
glutamine - Drug Profile 191
epoetin zeta - Drug Profile 193
epoetin alfa - Drug Profile 195
decitabine - Drug Profile 197
zileuton CR - Drug Profile 198
ST-10 - Drug Profile 199
carbon monoxide MP-4 - Drug Profile 201
ZFP Transcription Factors For Hemoglobinopathies - Drug Profile 202
LG-5640 - Drug Profile 203
PBI-4050 - Drug Profile 204
PEG-EPO - Drug Profile 205
MOD-7023 - Drug Profile 206
ALN-HPN - Drug Profile 207
epoetin alfa Long Acting - Drug Profile 208
LY-2928057 - Drug Profile 209
PBI-4494 - Drug Profile 210
epoetin - Drug Profile 211
BBT-021 - Drug Profile 212
BBT-009 - Drug Profile 213
Sanguinate - Drug Profile 214
poloxamer - Drug Profile 215
ZP-EPO - Drug Profile 216
Drug For Sickle Cell Anemia - Drug Profile 217
BAY-853934 - Drug Profile 218
DA-3880 - Drug Profile 219
epoetin alfa - Drug Profile 220
salsalate - Drug Profile 221
PNQ-103 - Drug Profile 222
darbepoetin alfa biosimilar - Drug Profile 223
JTZ-951 - Drug Profile 224
Recombinant Human Erythropoetin-Fc - Drug Profile 225
erythropoietin biosimilar - Drug Profile 226
Drug Targeting BCL11A - Drug Profile 227
MSKCC Product - Drug Profile 228
levamisole hydrochloride + [prednisolone] - Drug Profile 229
PLX Cells for Aplastic Bone Marrow - Drug Profile 230
ALN-TMP - Drug Profile 231
tetrahydrouridine + [decitabine] - Drug Profile 232
Erythropoietin Biosimilar - Drug Profile 233
Lentiviral-Mediated Gene Therapy - Drug Profile 234
AIC-6020 - Drug Profile 235
Drug For Fanconi Anemia - Drug Profile 236
HDAC1/2 Inhibitor - Drug Profile 237
HemaXellerate - Drug Profile 238
NKTT-120 - Drug Profile 239
CJ-40001 - Drug Profile 240
Pegylated Recombinant Human Erythropoietin - Drug Profile 241
ferrous sulfate - Drug Profile 242
VitalHeme - Drug Profile 243
VIT-91 - Drug Profile 244
PT-30 - Drug Profile 245
MM-P01-01 - Drug Profile 246
Drug For Sickle Cell Disease - Drug Profile 247
APL-0614 - Drug Profile 248
FMX-8 - Drug Profile 249
Sickle Cell Disease Program - Drug Profile 250
EdX-17 - Drug Profile 251
Pyruvate Kinase M2 Activator - Drug Profile 252
Pegylated Recombinant Human Erythropoietin Alpha - Drug Profile 253
Anemia Therapeutics - Drug Profile Updates 254
Anemia Therapeutics - Discontinued Products 309
Anemia Therapeutics - Dormant Products 310
Influenza A Infections - Product Development Milestones 313
Featured News and Press Releases 313
Appendix 321
Methodology 321
Coverage 321
Secondary Research 321
Primary Research 321
Expert Panel Validation 321
Contact Us 322
Disclaimer 322



List of Tables

Number of Products Under Development for Anemia, H2 2013 20
Products under Development for Anemia - Comparative Analysis, H2 2013 21
Number of Products under Development by Companies, H2 2013 23
Number of Products under Development by Companies, H2 2013 (Contd..1) 24
Number of Products under Development by Companies, H2 2013 (Contd..2) 25
Number of Products under Development by Companies, H2 2013 (Contd..3) 26
Number of Products under Development by Companies, H2 2013 (Contd..4) 27
Number of Products under Development by Companies, H2 2013 (Contd..5) 28
Number of Products under Investigation by Universities/Institutes, H2 2013 30
Comparative Analysis by Late Stage Development, H2 2013 31
Comparative Analysis by Mid Clinical Stage Development, H2 2013 32
Comparative Analysis by Early Clinical Stage Development, H2 2013 33
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 34
Products under Development by Companies, H2 2013 35
Products under Development by Companies, H2 2013 (Contd..1) 36
Products under Development by Companies, H2 2013 (Contd..2) 37
Products under Development by Companies, H2 2013 (Contd..3) 38
Products under Development by Companies, H2 2013 (Contd..4) 39
Products under Development by Companies, H2 2013 (Contd..5) 40
Products under Development by Companies, H2 2013 (Contd..6) 41
Products under Investigation by Universities/Institutes, H2 2013 42
Johnson and Johnson, H2 2013 43
Hospira, Inc., H2 2013 44
Medgenics Inc., H2 2013 45
AMAG Pharmaceuticals, Inc., H2 2013 46
Medinox, Inc., H2 2013 47
Amgen Inc., H2 2013 48
Eli Lilly and Company, H2 2013 49
GlaxoSmithKline plc, H2 2013 50
Sangart, Inc., H2 2013 51
Rockwell Medical Technologies, Inc., H2 2013 52
Daiichi Sankyo Company, Ltd, H2 2013 53
Lentigen Corporation, H2 2013 54
Sangamo BioSciences, Inc., H2 2013 55
FibroGen, Inc., H2 2013 57
Reliance Life Sciences Pvt. Ltd., H2 2013 58
Novartis AG, H2 2013 59
Astellas Pharma Inc., H2 2013 60
Chong Kun Dang Pharmaceutical, H2 2013 61
Dong-A Pharmaceutical Co., Ltd., H2 2013 62
Japan Tobacco Inc., H2 2013 63
Sandoz GmbH, H2 2013 64
ViroPharma Incorporated, H2 2013 65
Zydus Cadila Healthcare Limited, H2 2013 66
Bayer AG, H2 2013 67
Zosano Pharma, Inc., H2 2013 68
3SBio Inc., H2 2013 69
Evotec Aktiengesellschaft, H2 2013 70
Ligand Pharmaceuticals Incorporated, H2 2013 71
PROLOR Biotech, Inc., H2 2013 72
ReGenX Biosciences, LLC, H2 2013 73
Accentia Biopharmaceuticals, Inc., H2 2013 74
ADVENTRX Pharmaceuticals, H2 2013 75
Alexion Pharmaceuticals, Inc., H2 2013 76
Alnylam Pharmaceuticals, Inc, H2 2013 77
Zenotech Laboratories Limited, H2 2013 78
ProMetic Life Sciences Inc., H2 2013 79
Lipoxen PLC, H2 2013 80
Boryung Pharmaceutical Co., Ltd., H2 2013 81
Green Cross Corporation, H2 2013 82
Hanall Pharmaceutical Co., Ltd., H2 2013 83
JCR Pharmaceuticals Co., Ltd., H2 2013 84
CCM Duopharma Biotech Bhd., H2 2013 85
Pluristem Therapeutics Inc., H2 2013 86
Uni-Bio Science Group Ltd., H2 2013 87
Panacea Biotec Limited, H2 2013 88
Affymax, Inc., H2 2013 89
Panion and Bf Biotech Inc., H2 2013 90
Myungmoon pharmaceutical Co.,Ltd., H2 2013 91
Cellerant Therapeutics, Inc., H2 2013 92
Advinus Therapeutics Pvt. Ltd., H2 2013 93
Asterion Ltd, H2 2013 94
CIMAB S.A., H2 2013 95
Prolong Pharmaceuticals, H2 2013 96
Acceleron Pharma, Inc., H2 2013 97
SynZyme Technologies, LLC, H2 2013 98
Pieris AG, H2 2013 99
Xenon Pharmaceuticals Inc., H2 2013 100
ERYtech Pharma, H2 2013 101
Archemix Corp., H2 2013 102
HemaQuest Pharmaceuticals, Inc., H2 2013 103
Akebia Therapeutics, Inc., H2 2013 104
GENETIX Pharmaceuticals, Inc., H2 2013 105
NOXXON Pharma AG, H2 2013 106
Morphogenesis, Inc., H2 2013 107
NKT Therapeutics, Inc., H2 2013 108
Bolder Biotechnology, Inc., H2 2013 109
Palkion, Inc., H2 2013 110
Acetylon Pharmaceuticals, Inc., H2 2013 111
Emmaus Medical, Inc., H2 2013 112
Avesthagen Limited, H2 2013 113
PharmaEssentia Corporation, H2 2013 114
Vifor Pharma Ltd., H2 2013 115
AesRx, LLC., H2 2013 116
Errant Gene Therapeutics, LLC, H2 2013 117
NAL Pharmaceuticals Ltd., H2 2013 118
Assessment by Monotherapy Products, H2 2013 119
Assessment by Combination Products, H2 2013 120
Anemia Therapeutics - Drug Profile Updates 261
Anemia Therapeutics - Discontinued Products 324
Anemia Therapeutics - Dormant Products 325
Anemia Therapeutics - Dormant Products (Contd..1) 326
Anemia Therapeutics - Dormant Products (Contd..2) 327



List of Figures

Number of Products under Development for Anemia, H2 2013 20
Products under Development for Anemia - Comparative Analysis, H2 2013 21
Products under Development by Companies, H2 2013 22
Products under Investigation by Universities/Institutes, H2 2013 29
Late Stage Products, H2 2013 31
Mid Clinical Stage Products, H2 2013 32
Early Clinical Stage Products, H2 2013 33
Discovery and Pre-Clinical Stage Products, H2 2013 34
Assessment by Monotherapy Products, H2 2013 119
Assessment by Combination Products, H2 2013 120



Companies Mentioned

Johnson and Johnson
Hospira, Inc.
Medgenics Inc.
AMAG Pharmaceuticals, Inc.
Medinox, Inc.
Amgen Inc.
Eli Lilly and Company
GlaxoSmithKline plc
Sangart, Inc.
Rockwell Medical Technologies, Inc.
Daiichi Sankyo Company, Ltd
Lentigen Corporation
Sangamo BioSciences, Inc.
Gamida Cell Ltd.
FibroGen, Inc.
Reliance Life Sciences Pvt. Ltd.
Novartis AG
Astellas Pharma Inc.
Chong Kun Dang Pharmaceutical
Dong-A Pharmaceutical Co., Ltd.
Japan Tobacco Inc.
Sandoz GmbH
ViroPharma Incorporated
Zydus Cadila Healthcare Limited
Bayer AG
Zosano Pharma, Inc.
3SBio Inc.
Evotec Aktiengesellschaft
Ligand Pharmaceuticals Incorporated
PROLOR Biotech, Inc.
ReGenX Biosciences, LLC
Accentia Biopharmaceuticals, Inc.
ADVENTRX Pharmaceuticals
Alexion Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc
Zenotech Laboratories Limited
ProMetic Life Sciences Inc.
Lipoxen PLC
Boryung Pharmaceutical Co., Ltd.
Green Cross Corporation
Hanall Pharmaceutical Co., Ltd.
JCR Pharmaceuticals Co., Ltd.
CCM Duopharma Biotech Bhd.
Pluristem Therapeutics Inc.
Uni-Bio Science Group Ltd.
Panacea Biotec Limited
Affymax, Inc.
Panion and Bf Biotech Inc.
Myungmoon pharmaceutical Co.,Ltd.
Cellerant Therapeutics, Inc.
Advinus Therapeutics Pvt. Ltd.
Asterion Ltd
CIMAB S.A.
Prolong Pharmaceuticals
Acceleron Pharma, Inc.
SynZyme Technologies, LLC
Pieris AG
Xenon Pharmaceuticals Inc.
ERYtech Pharma
Archemix Corp.
HemaQuest Pharmaceuticals, Inc.
Akebia Therapeutics, Inc.
GENETIX Pharmaceuticals, Inc.
NOXXON Pharma AG
Morphogenesis, Inc.
NKT Therapeutics, Inc.
Bolder Biotechnology, Inc.
Palkion, Inc.
Acetylon Pharmaceuticals, Inc.
Emmaus Medical, Inc.
Avesthagen Limited
PharmaEssentia Corporation
Vifor Pharma Ltd.
AesRx, LLC.
Errant Gene Therapeutics, LLC
NAL Pharmaceuticals Ltd.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market and Hypertension Statistics in Asia and the US

  • November 2016
    26 pages
  • Therapy  

    Hypertension  

    Cardiovascular ...  

  • Asia  

    United States  

    Europe  

View report >

Global Eye Disease Statistics

  • November 2016
    7 pages
  • Eye Disease  

  • World  

    Tanzania  

View report >

Infectious Disease Statistics in South Africa

  • November 2016
    9 pages
  • Infectious Dise...  

  • South Africa  

    Africa  

View report >

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.